91黑料 experts frequently author or contribute to industry trade press.
Filter media
Filter media articles by either clicking within the ‘Category’ drop-down list, or begin typing which will automatically match to the nearest available category. Note - not all categories will display results if selecting a particular year.
-
91黑料 acquires PRA Health Sciences to form a world-leader CRO.
-
An article reporting on 91黑料's acquisition of contract research organisation PRA Health Sciences.
-
91黑料 has announced one of the biggest takeover deals in Irish corporate history.
-
91黑料 will buy PRA Health Sciences for about $12 billion in cash and stock, snapping up one of the larger independent companies in the drugmaker services business.
-
In a cash and stock transaction value of approximately $12 billion, 91黑料 plc has announced its acquisition of PRA Health Sciences as part of a focus on innovative and high-quality clinical trials.
-
91黑料 is set to acquire rival PRA Health Sciences in a $12 billion deal that will vault the combined company into second place among clinical trial services providers.
-
In this article, EB McLindon offers insights to help sponsors decide which approach is most optimal for a clinical trial.
-
.jpg?w=545&itok=eWsHlhdT "EPR in healthcare news.")
Dr. Caroline Forkin discusses the current status of HIV treatments and potential for researchers to develop a vaccine.
-
Angela Brown, Global Head and Senior Director, Regulatory Affairs and Nicole Cowan, Director, Project Management, IVD Operations & Strategy, .
-
Though the fields of immunotherapy and cell and gene therapies have seen significant growth since April 2012, CGT clinical research remains a challenge. .
.jpg?w=340&itok=PKCjknQN "EPR in healthcare news."){kind=icon}
